A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
Study Details
Study Description
Brief Summary
This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel Pyrotinib tablets: 320mg qd, 21 days for 1 cycle, continuous administration of 6 cycles. Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles. Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given. Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration |
Drug: pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles.
Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.
Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.
Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration
|
Outcome Measures
Primary Outcome Measures
- total Pathological Complete Response(tPCR) [2 years]
Secondary Outcome Measures
- breast Pathological Complete Response(bPCR) [2 years]
- overall response rate(ORR) [2 years]
- event-free survival(EFS) [5 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Newly treated female patients aged ≥18 years and ≤75 years;
-
ECOG score 0~1;
-
Pathologically diagnosed as HER2-positive breast cancer patients with early or locally advanced tumor stage, primary tumor diameter T≥2cm or lymph node positive;
-
Hormone receptor status (ER and PgR) is known, where ER≥10%
-
Normal function of major organs:
-
The standard of blood routine examination should meet: ANC ≥1.5×109/L; PLT≥90×109/L; Hb ≥90g/L
-
Biochemical examination should meet the following standards: TBIL≤ the upper limit of normal value(ULN); ALT and AST≤1.5 times the upper limit of normal (ULN); Alkaline phosphatase ≤2.5 times the upper limit of normal (ULN); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (CockcroftGault formula);
-
Cardiac color ultrasound and echocardiography: left ventricular ejection fraction(LVEF≥55%)
-
Fridericia calibrated QT interval (QTcF) for 18-lead ECG <470 ms;
-
For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence or use of an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment;
-
Volunteer to join the study and sign the informed consent.
Exclusion Criteria:
-
Stage IV (metastatic) breast cancer;
-
Inflammatory breast cancer;
-
Previous antitumor therapy or radiation therapy for any malignancies, excluding cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma;
-
Also receiving antitumor therapy in other clinical trials, including endocrine therapy, bisphosphonate therapy, or immunotherapy;
-
Had a major surgery not related to breast cancer in the 4 weeks prior to enrollment, or had not fully recovered from such surgery;
-
Serious heart disease or discomfort, including but not limited to the following:
-
History of heart failure or systolic dysfunction (LVEF < 50%)
-
High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate >100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-grade atrioventricular block (i.e. Mobitz II second- degree atrioventricular block or third-degree atrioventricular block
-
Inability to swallow, intestinal obstruction, or other factors affecting the use and absorption of the drug;
-
Known allergic history of the drug components of this protocol; A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
-
Women who are pregnant or nursing, women who are fertile and have a positive baseline pregnancy test, or women of childbearing age who are unwilling to use effective contraception throughout the trial period and within 7 months after the last study medication;
-
Have a serious concomitant condition or other comorbid condition that interferes with planned treatment, or any other condition in which the investigator deems the patient unsuitable for participation in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | WuhanHU | Wuhan | Hubei | China | 430000 |
| 2 | Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | China |
Sponsors and Collaborators
- Wuhan Union Hospital, China
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UHCT22745